ethambutol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1073	74-55-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ethambutol etambutol diambutol (S,S)-Ethambutol ethambutol hydrochloride ethambutol dihydrochloride ethambutol HCl	An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Molecular weight: 204.31 Formula: C10H24N2O2 CLOGP: 0.12 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 64.52 ALOGS: -1.43 ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ethambutol
etambutol
diambutol
(S,S)-Ethambutol
ethambutol hydrochloride
ethambutol dihydrochloride
ethambutol HCl

An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)

Molecular weight: 204.31
Formula: C10H24N2O2
CLOGP: 0.12
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 64.52
ALOGS: -1.43
ROTB: 9

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	g	O
1.20	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	79 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	122.36 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	77 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.18 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 6, 1967	FDA	STI PHARMA LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	648.16	18.96	237	10760	33599	63444426
Drug resistance	455.05	18.96	165	10832	22768	63455257
Paradoxical drug reaction	439.54	18.96	109	10888	4043	63473982
Drug-induced liver injury	333.82	18.96	155	10842	40067	63437958
Immune reconstitution inflammatory syndrome	293.95	18.96	86	10911	5998	63472027
Acute hepatic failure	234.85	18.96	96	10901	18231	63459794
Drug interaction	189.36	18.96	215	10782	228916	63249109
Tuberculoma of central nervous system	187.96	18.96	35	10962	312	63477713
Optic neuropathy	173.73	18.96	45	10952	1987	63476038
Hepatotoxicity	159.75	18.96	92	10905	36949	63441076
Mycobacterium avium complex infection	159.53	18.96	46	10951	3042	63474983
Immune reconstitution inflammatory syndrome associated tuberculosis	142.33	18.96	28	10969	342	63477683
Rash maculo-papular	121.16	18.96	73	10924	31823	63446202
Jaundice	108.66	18.96	66	10931	29185	63448840
Hepatic encephalopathy	104.52	18.96	47	10950	11235	63466790
Hepatitis	104.02	18.96	72	10925	39716	63438309
Optic neuritis	103.97	18.96	43	10954	8392	63469633
Pancreatitis haemorrhagic	87.68	18.96	20	10977	513	63477512
Pulmonary tuberculosis	87.58	18.96	32	10965	4485	63473540
Hepatocellular injury	87.11	18.96	56	10941	27325	63450700
Tuberculosis	86.06	18.96	41	10956	11170	63466855
Eosinophilia	78.53	18.96	49	10948	22707	63455318
Pyrexia	76.88	18.96	216	10781	470262	63007763
Pathogen resistance	73.42	18.96	31	10966	6367	63471658
Distributive shock	64.35	18.96	19	10978	1364	63476661
Neuropathy peripheral	62.17	18.96	87	10910	113580	63364445
Transaminases increased	62.09	18.96	48	10949	31319	63446706
Hepatic function abnormal	61.11	18.96	51	10946	37091	63440934
Hypertransaminasaemia	59.51	18.96	27	10970	6582	63471443
Hepatitis toxic	59.21	18.96	22	10975	3231	63474794
Disseminated tuberculosis	58.15	18.96	21	10976	2846	63475179
Hepatitis fulminant	57.86	18.96	22	10975	3442	63474583
Product use in unapproved indication	53.08	18.96	104	10893	178976	63299049
Hepatitis B	52.33	18.96	21	10976	3791	63474234
Alanine aminotransferase increased	50.26	18.96	75	10922	103695	63374330
Pain	48.22	18.96	35	10962	740593	62737432
Ocular toxicity	47.72	18.96	13	10984	697	63477328
Mycobacterial infection	47.48	18.96	16	10981	1767	63476258
Toxic optic neuropathy	46.94	18.96	10	10987	185	63477840
Oedematous kidney	45.66	18.96	9	10988	111	63477914
Oedematous pancreatitis	45.48	18.96	12	10985	569	63477456
Hepatic cytolysis	45.29	18.96	30	10967	15377	63462648
Aspartate aminotransferase increased	44.79	18.96	66	10931	90211	63387814
Uveitis	43.22	18.96	27	10970	12526	63465499
Drug ineffective for unapproved indication	42.51	18.96	40	10957	34023	63444002
Multiple organ dysfunction syndrome	41.23	18.96	50	10947	56702	63421323
Granuloma	40.97	18.96	20	10977	5741	63472284
Tuberculosis gastrointestinal	40.49	18.96	10	10987	363	63477662
Drug level decreased	40.44	18.96	22	10975	7897	63470128
Visual acuity reduced	40.17	18.96	32	10965	21794	63456231
Cholestatic liver injury	37.99	18.96	15	10982	2595	63475430
Atypical mycobacterial infection	37.91	18.96	12	10985	1088	63476937
Meningitis tuberculous	35.89	18.96	10	10987	583	63477442
Thrombocytopenia	35.67	18.96	80	10917	151077	63326948
Aspergillus infection	34.58	18.96	20	10977	8073	63469952
Fatigue	34.07	18.96	64	10933	887964	62590061
Ototoxicity	31.51	18.96	11	10986	1351	63476674
Multiple-drug resistance	31.03	18.96	16	10981	5154	63472871
Choroiditis	30.27	18.96	7	10990	191	63477834
Tinnitus	30.23	18.96	34	10963	35594	63442431
Hepatic failure	30.21	18.96	34	10963	35622	63442403
Pain in extremity	30.04	18.96	10	10987	331476	63146549
Lymphadenopathy	29.76	18.96	35	10962	38423	63439602
Haemolysis	29.65	18.96	17	10980	6751	63471274
Lymph node tuberculosis	28.72	18.96	9	10988	790	63477235
Pigment nephropathy	27.56	18.96	5	10992	38	63477987
Arthropathy	27.45	18.96	4	10993	234788	63243237
Liver transplant rejection	27.20	18.96	10	10987	1425	63476600
Transplant rejection	26.96	18.96	19	10978	10761	63467264
Infusion related reaction	26.89	18.96	5	10992	245516	63232509
Gamma-glutamyltransferase increased	26.38	18.96	31	10966	34000	63444025
Joint swelling	26.20	18.96	12	10985	327654	63150371
Fall	26.16	18.96	18	10979	392316	63085709
Alopecia	26.01	18.96	13	10984	337523	63140502
Cryptococcosis	25.45	18.96	9	10988	1148	63476877
Mastitis bacterial	25.27	18.96	5	10992	63	63477962
Pancreatitis acute	24.90	18.96	27	10970	27139	63450886
Vomiting	24.41	18.96	173	10824	559444	62918581
Acid fast bacilli infection	24.27	18.96	5	10992	78	63477947
Hepatitis cholestatic	24.20	18.96	15	10982	6863	63471162
Rheumatoid arthritis	24.16	18.96	7	10990	253812	63224213
Visual impairment	23.72	18.96	48	10949	84398	63393627
Clostridium difficile colitis	23.47	18.96	23	10974	20546	63457479
Systemic lupus erythematosus	23.43	18.96	4	10993	208914	63269111
Disseminated intravascular coagulation	23.05	18.96	22	10975	19029	63458996
Pseudomembranous colitis	22.72	18.96	11	10986	3101	63474924
Visual field defect	22.30	18.96	14	10983	6547	63471478
Deafness	22.23	18.96	21	10976	17936	63460089
Sinusitis	22.04	18.96	6	10991	226647	63251378
Myopathy	21.86	18.96	17	10980	11174	63466851
Disseminated mycobacterium avium complex infection	21.85	18.96	5	10992	130	63477895
Jarisch-Herxheimer reaction	21.19	18.96	6	10991	371	63477654
Therapeutic product effect decreased	21.01	18.96	4	10993	193183	63284842
Peripheral swelling	20.85	18.96	10	10987	265932	63212093
Swelling	20.62	18.96	11	10986	275367	63202658
Infection	20.60	18.96	7	10990	229166	63248859
Type IV hypersensitivity reaction	20.42	18.96	10	10987	2888	63475137
Pneumothorax	20.10	18.96	19	10978	16242	63461783
Deafness bilateral	19.99	18.96	8	10989	1434	63476591
Intracranial pressure increased	19.92	18.96	12	10985	5215	63472810
Blood bilirubin increased	19.64	18.96	28	10969	37112	63440913
Immune system disorder	19.34	18.96	15	10982	9819	63468206
Pneumatosis intestinalis	19.05	18.96	9	10988	2404	63475621
Contraindicated product administered	18.96	18.96	7	10990	217641	63260384

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paradoxical drug reaction	810.87	19.34	201	13642	3150	34939938
Immune reconstitution inflammatory syndrome	669.10	19.34	213	13630	8546	34934542
Drug-induced liver injury	399.79	19.34	205	13638	28627	34914461
Drug resistance	370.02	19.34	188	13655	25739	34917349
Drug reaction with eosinophilia and systemic symptoms	324.70	19.34	187	13656	32825	34910263
Hepatotoxicity	281.07	19.34	147	13696	21338	34921750
Immune reconstitution inflammatory syndrome associated tuberculosis	231.23	19.34	50	13793	408	34942680
Optic neuropathy	210.35	19.34	62	13781	1903	34941185
Jaundice	193.32	19.34	133	13710	31749	34911339
Tuberculosis	166.91	19.34	77	13766	8500	34934588
Mycobacterial infection	165.78	19.34	54	13789	2320	34940768
Tuberculoma of central nervous system	145.60	19.34	31	13812	233	34942855
Drug interaction	126.79	19.34	277	13566	225669	34717419
Hepatitis	113.45	19.34	86	13757	23818	34919270
Optic neuritis	112.15	19.34	45	13798	3529	34939559
Mycobacterium avium complex infection	97.85	19.34	37	13806	2474	34940614
Immune system disorder	96.63	19.34	45	13798	5070	34938018
Drug level decreased	78.46	19.34	45	13798	7801	34935287
Pulmonary tuberculosis	72.16	19.34	36	13807	4718	34938370
Toxic optic neuropathy	70.31	19.34	22	13821	828	34942260
Ocular toxicity	66.25	19.34	16	13827	222	34942866
Granuloma	65.77	19.34	30	13813	3221	34939867
Hepatic failure	64.76	19.34	74	13769	34457	34908631
Hydrocephalus	63.24	19.34	34	13809	5198	34937890
Disseminated tuberculosis	63.13	19.34	26	13817	2179	34940909
Death	60.57	19.34	42	13801	398007	34545081
Condition aggravated	60.40	19.34	190	13653	192006	34751082
Lymphadenopathy	60.26	19.34	65	13778	28398	34914690
Skin disorder	58.25	19.34	46	13797	13509	34929579
Pyrexia	58.25	19.34	273	13570	332740	34610348
Tuberculosis of central nervous system	58.06	19.34	14	13829	193	34942895
Liver function test abnormal	57.27	19.34	66	13777	31008	34912080
Acute hepatic failure	54.62	19.34	45	13798	14029	34929059
Atypical mycobacterial infection	53.10	19.34	18	13825	875	34942213
Thalamic infarction	51.43	19.34	17	13826	764	34942324
Meningitis tuberculous	49.52	19.34	16	13827	669	34942419
Phalangeal hypoplasia	47.58	19.34	10	13833	70	34943018
Multiple-drug resistance	46.97	19.34	28	13815	5211	34937877
Sideroblastic anaemia	45.25	19.34	12	13831	247	34942841
Rash maculo-papular	43.54	19.34	55	13788	28396	34914692
Hepatic function abnormal	43.06	19.34	69	13774	44294	34898794
Diaphragmatic injury	42.30	19.34	10	13833	126	34942962
Transaminases increased	41.28	19.34	52	13791	26771	34916317
Lymphopenia	41.22	19.34	41	13802	16294	34926794
Tuberculosis gastrointestinal	41.18	19.34	11	13832	233	34942855
Eosinophilia	40.61	19.34	51	13792	26171	34916917
Pancytopenia	40.45	19.34	105	13738	95052	34848036
Ototoxicity	39.76	19.34	18	13825	1899	34941189
Tuberculosis of eye	39.72	19.34	8	13835	44	34943044
Blindness	38.53	19.34	38	13805	14948	34928140
Splenic embolism	38.52	19.34	10	13833	189	34942899
Mixed liver injury	38.49	19.34	20	13823	2853	34940235
Pathogen resistance	38.22	19.34	31	13812	9451	34933637
Fall	37.09	19.34	17	13826	202868	34740220
Mycobacterium abscessus infection	36.46	19.34	12	13831	532	34942556
Tubulointerstitial nephritis	35.97	19.34	43	13800	20981	34922107
Chylothorax	35.92	19.34	13	13830	768	34942320
Granulomatous liver disease	34.98	19.34	12	13831	605	34942483
Hepatocellular injury	34.08	19.34	43	13800	22168	34920920
Unmasking of previously unidentified disease	33.92	19.34	13	13830	901	34942187
Vitamin B1 decreased	33.27	19.34	10	13833	328	34942760
Thrombocytopenia	33.18	19.34	136	13707	156111	34786977
Product use in unapproved indication	32.19	19.34	111	13732	117388	34825700
Hepatitis fulminant	31.46	19.34	20	13823	4170	34938918
Bone tuberculosis	31.44	19.34	10	13833	397	34942691
Colour blindness	31.38	19.34	9	13834	250	34942838
Congenital foot malformation	30.63	19.34	10	13833	432	34942656
Pain	29.20	19.34	23	13820	204652	34738436
Acid fast bacilli infection	28.67	19.34	7	13836	102	34942986
Drug ineffective	28.21	19.34	290	13553	456461	34486627
Cachexia	27.92	19.34	23	13820	7163	34935925
Pulmonary cavitation	26.74	19.34	11	13832	919	34942169
Cytomegalovirus chorioretinitis	26.62	19.34	17	13826	3572	34939516
Splenic infarction	26.52	19.34	14	13829	2061	34941027
Cholestasis	26.25	19.34	42	13801	26906	34916182
Electrocardiogram QT prolonged	26.03	19.34	53	13790	40899	34902189
Visual acuity reduced	25.95	19.34	32	13811	16117	34926971
Macular degeneration	25.84	19.34	14	13829	2172	34940916
Type III immune complex mediated reaction	25.52	19.34	8	13835	303	34942785
Autoimmune haemolytic anaemia	25.43	19.34	18	13825	4478	34938610
Atypical mycobacterium test positive	25.22	19.34	5	13838	25	34943063
Pulmonary granuloma	24.44	19.34	12	13831	1518	34941570
Fatigue	24.43	19.34	71	13772	370582	34572506
Purpura	24.40	19.34	25	13818	10286	34932802
Leukopenia	24.30	19.34	67	13776	62789	34880299
Febrile neutropenia	24.17	19.34	12	13831	136837	34806251
Lymphadenitis	24.00	19.34	13	13830	2015	34941073
Neuropathy peripheral	23.96	19.34	80	13763	83183	34859905
Splenic abscess	23.90	19.34	8	13835	374	34942714
Hyperuricaemia	23.72	19.34	22	13821	8021	34935067
Drug eruption	23.62	19.34	34	13809	19864	34923224
Product dose omission issue	23.51	19.34	9	13834	119702	34823386
Liver transplant rejection	23.47	19.34	13	13830	2106	34940982
Pulmonary sequestration	23.20	19.34	5	13838	40	34943048
Cardiac failure congestive	22.82	19.34	3	13840	83267	34859821
Atrial fibrillation	22.74	19.34	10	13833	122383	34820705
Diarrhoea	22.67	19.34	79	13764	389833	34553255
Blood pressure increased	22.26	19.34	4	13839	88098	34854990
Implant site infection	21.86	19.34	10	13833	1080	34942008
Dilatation intrahepatic duct acquired	21.37	19.34	5	13838	60	34943028
Constipation	21.34	19.34	14	13829	136968	34806120
Marrow hyperplasia	21.24	19.34	10	13833	1153	34941935
Herpes zoster meningoencephalitis	21.15	19.34	7	13836	316	34942772
Renal atrophy	21.06	19.34	10	13833	1175	34941913
Urinary tract inflammation	20.80	19.34	6	13837	170	34942918
Hereditary optic atrophy	20.71	19.34	4	13839	17	34943071
Trisomy 21	20.54	19.34	8	13835	579	34942509
Nephropathy toxic	20.31	19.34	25	13818	12563	34930525
Pericarditis tuberculous	20.22	19.34	5	13838	77	34943011
Liver disorder	20.14	19.34	42	13801	32955	34910133
Alanine aminotransferase increased	20.10	19.34	74	13769	80741	34862347
Protrusion tongue	20.08	19.34	6	13837	193	34942895
Encephalitis	19.73	19.34	19	13824	7258	34935830
Cell death	19.58	19.34	12	13831	2345	34940743
Intra-abdominal haemorrhage	19.37	19.34	12	13831	2392	34940696

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paradoxical drug reaction	1169.69	17.13	295	22858	6890	79714345
Drug reaction with eosinophilia and systemic symptoms	903.89	17.13	418	22735	63826	79657409
Immune reconstitution inflammatory syndrome	888.48	17.13	274	22879	13567	79707668
Drug resistance	702.41	17.13	309	22844	41904	79679331
Drug-induced liver injury	676.05	17.13	346	22807	65771	79655464
Hepatotoxicity	428.99	17.13	235	22918	51117	79670118
Immune reconstitution inflammatory syndrome associated tuberculosis	372.63	17.13	78	23075	758	79720477
Optic neuropathy	369.81	17.13	102	23051	3382	79717853
Drug interaction	320.69	17.13	490	22663	414693	79306542
Jaundice	310.02	17.13	193	22960	53156	79668079
Tuberculoma of central nervous system	309.75	17.13	63	23090	524	79720711
Acute hepatic failure	285.53	17.13	150	23003	29963	79691272
Tuberculosis	226.10	17.13	103	23050	15095	79706140
Mycobacterium avium complex infection	216.53	17.13	72	23081	4528	79716707
Toxic optic neuropathy	195.71	17.13	49	23104	1104	79720131
Optic neuritis	195.50	17.13	81	23072	9439	79711796
Mycobacterial infection	174.99	17.13	58	23095	3610	79717625
Hepatitis	172.16	17.13	137	23016	55590	79665645
Pulmonary tuberculosis	155.03	17.13	65	23088	7800	79713435
Rash maculo-papular	146.32	17.13	125	23028	55953	79665282
Pyrexia	125.96	17.13	457	22696	678252	79042983
Immune system disorder	116.18	17.13	59	23094	10970	79710265
Disseminated tuberculosis	115.21	17.13	44	23109	4139	79717096
Drug level decreased	112.14	17.13	63	23090	14339	79706896
Eosinophilia	110.04	17.13	97	23056	45248	79675987
Hepatic failure	104.83	17.13	108	23045	61104	79660131
Hepatocellular injury	100.18	17.13	94	23059	47499	79673736
Hepatic function abnormal	94.03	17.13	111	23042	72996	79648239
Granuloma	92.13	17.13	46	23107	8251	79712984
Transaminases increased	89.87	17.13	92	23061	51651	79669584
Ocular toxicity	89.83	17.13	25	23128	856	79720379
Lymphadenopathy	89.47	17.13	93	23060	53154	79668081
Neuropathy peripheral	88.36	17.13	152	23001	141153	79580082
Meningitis tuberculous	86.38	17.13	26	23127	1179	79720056
Pain	84.47	17.13	50	23103	703752	79017483
Pathogen resistance	83.50	17.13	52	23101	14290	79706945
Hepatic encephalopathy	82.36	17.13	63	23090	24103	79697132
Hepatitis fulminant	76.93	17.13	39	23114	7223	79714012
Pancreatitis haemorrhagic	73.07	17.13	21	23132	809	79720426
Atypical mycobacterial infection	73.02	17.13	25	23128	1718	79719517
Hydrocephalus	72.20	17.13	40	23113	8860	79712375
Thrombocytopenia	70.14	17.13	202	22951	265057	79456178
Fall	70.12	17.13	27	23126	487602	79233633
Ototoxicity	67.69	17.13	28	23125	3246	79717989
Visual acuity reduced	67.43	17.13	61	23092	29408	79691827
Tuberculosis gastrointestinal	66.45	17.13	18	23135	556	79720679
Hepatitis toxic	64.51	17.13	31	23122	5116	79716119
Multiple-drug resistance	64.45	17.13	37	23116	8771	79712464
Fatigue	59.96	17.13	112	23041	929615	78791620
Tuberculosis of central nervous system	59.61	17.13	16	23137	477	79720758
Alanine aminotransferase increased	58.51	17.13	139	23014	162431	79558804
Sideroblastic anaemia	58.12	17.13	14	23139	267	79720968
Death	55.23	17.13	50	23103	566464	79154771
Liver function test abnormal	55.00	17.13	80	23073	64395	79656840
Mixed liver injury	53.23	17.13	31	23122	7547	79713688
Joint swelling	52.66	17.13	10	23143	288636	79432599
Infusion related reaction	51.67	17.13	4	23149	230233	79491002
Liver transplant rejection	51.42	17.13	23	23130	3225	79718010
Skin disorder	51.19	17.13	56	23097	33887	79687348
Mycobacterium abscessus infection	49.14	17.13	17	23136	1205	79720030
Lymph node tuberculosis	48.23	17.13	16	23137	998	79720237
Nasopharyngitis	48.04	17.13	8	23145	253873	79467362
Thalamic infarction	48.02	17.13	17	23136	1290	79719945
Granulomatous liver disease	47.70	17.13	17	23136	1316	79719919
Distributive shock	45.67	17.13	20	23133	2667	79718568
Diaphragmatic injury	45.39	17.13	10	23143	126	79721109
Cholestatic liver injury	45.06	17.13	24	23129	4917	79716318
Hepatic cytolysis	44.83	17.13	47	23106	27104	79694131
Pancytopenia	44.50	17.13	127	23026	165618	79555617
Product use in unapproved indication	43.13	17.13	165	22988	250194	79471041
Acid fast bacilli infection	42.82	17.13	10	23143	166	79721069
Hypertransaminasaemia	42.64	17.13	32	23121	11892	79709343
Tubulointerstitial nephritis	40.99	17.13	53	23100	38182	79683053
Splenic embolism	40.97	17.13	10	23143	202	79721033
Uveitis	40.80	17.13	36	23117	16794	79704441
Lymphadenitis	40.74	17.13	22	23131	4633	79716602
Blindness	39.66	17.13	45	23108	28338	79692897
Cholestasis	39.22	17.13	61	23092	52048	79669187
Aspartate aminotransferase increased	37.96	17.13	107	23046	138534	79582701
Disseminated intravascular coagulation	37.36	17.13	49	23104	35793	79685442
Rheumatoid arthritis	36.40	17.13	8	23145	208462	79512773
Transplant rejection	36.37	17.13	36	23117	19401	79701834
Condition aggravated	36.14	17.13	259	22894	500865	79220370
Disseminated mycobacterium avium complex infection	35.72	17.13	9	23144	208	79721027
Oedematous kidney	35.72	17.13	9	23144	208	79721027
Electrocardiogram QT prolonged	35.48	17.13	80	23073	90306	79630929
Product dose omission issue	35.04	17.13	14	23139	247523	79473712
Aspergillus infection	34.95	17.13	35	23118	19126	79702109
Arthropathy	34.82	17.13	5	23148	177106	79544129
Hyperbilirubinaemia	34.47	17.13	39	23114	24479	79696756
Immunosuppressant drug level decreased	34.33	17.13	15	23138	1989	79719246
Hyperuricaemia	34.26	17.13	28	23125	11771	79709464
Dyspnoea	34.09	17.13	131	23022	856894	78864341
Colour blindness	33.96	17.13	10	23143	420	79720815
Unmasking of previously unidentified disease	33.95	17.13	15	23138	2042	79719193
Cachexia	33.66	17.13	27	23126	11056	79710179
Hepatitis B	33.50	17.13	24	23129	8308	79712927
Pain in extremity	33.34	17.13	34	23119	364504	79356731
Dizziness	33.30	17.13	64	23089	526377	79194858
Macular degeneration	33.21	17.13	27	23126	11269	79709966
Alopecia	32.89	17.13	13	23140	231342	79489893
Constipation	32.61	17.13	21	23132	283029	79438206
Peripheral swelling	32.46	17.13	19	23134	269598	79451637
Deafness	32.23	17.13	35	23118	21002	79700233
Vitamin B1 decreased	31.30	17.13	10	23143	553	79720682
Oedematous pancreatitis	31.14	17.13	12	23141	1156	79720079
Bone tuberculosis	31.01	17.13	10	23143	570	79720665
Pericarditis tuberculous	30.70	17.13	7	23146	104	79721131
Drug ineffective	29.80	17.13	459	22694	1080454	78640781
Headache	29.26	17.13	95	23058	653677	79067558
Drug ineffective for unapproved indication	29.25	17.13	53	23100	51185	79670050
Herpes zoster meningoencephalitis	28.35	17.13	10	23143	751	79720484
Deafness neurosensory	28.03	17.13	20	23133	6878	79714357
Peritoneal tuberculosis	28.00	17.13	9	23144	508	79720727
Nephropathy toxic	27.89	17.13	32	23121	20387	79700848
Bovine tuberculosis	27.82	17.13	7	23146	161	79721074
Lymphopenia	27.64	17.13	39	23114	30518	79690717
Pulmonary cavitation	27.09	17.13	12	23141	1644	79719591
Visual impairment	27.08	17.13	73	23080	92058	79629177
Lower respiratory tract infection	26.97	17.13	3	23150	129217	79592018
Hypertension	26.86	17.13	34	23119	330958	79390277
Type IV hypersensitivity reaction	26.84	17.13	16	23137	4065	79717170
Tuberculosis of eye	26.78	17.13	6	23147	82	79721153
Blood pressure increased	26.73	17.13	14	23139	211346	79509889
Cryptococcosis	26.43	17.13	15	23138	3478	79717757
Pulmonary sequestration	26.30	17.13	5	23148	28	79721207
Sinusitis	26.16	17.13	12	23141	195489	79525746
Hepatosplenomegaly	25.60	17.13	18	23135	6051	79715184
Leukopenia	25.38	17.13	83	23070	116430	79604805
Visual field defect	25.29	17.13	21	23132	9024	79712211
Mobility decreased	25.09	17.13	3	23150	122172	79599063
Hereditary optic atrophy	24.98	17.13	5	23148	38	79721197
Injection site pain	24.75	17.13	4	23149	129834	79591401
Muscle spasms	24.53	17.13	10	23143	174720	79546515
HIV infection	24.53	17.13	10	23143	1117	79720118
Drug eruption	24.51	17.13	45	23108	43890	79677345
Haemolytic anaemia	24.47	17.13	28	23125	17792	79703443
Pulmonary granuloma	24.26	17.13	12	23141	2109	79719126
Feeling abnormal	24.22	17.13	8	23145	159191	79562044
Pigment nephropathy	23.93	17.13	5	23148	48	79721187
Multiple organ dysfunction syndrome	23.84	17.13	83	23070	120163	79601072
Diarrhoea	23.82	17.13	154	22999	880335	78840900
Discomfort	23.65	17.13	4	23149	125613	79595622
Dyschromatopsia	23.55	17.13	9	23144	848	79720387
Lymph node abscess	23.15	17.13	5	23148	57	79721178
Weight increased	23.01	17.13	28	23125	277358	79443877
Bronchitis	22.82	17.13	5	23148	130639	79590596
Toxic epidermal necrolysis	22.80	17.13	44	23109	44537	79676698
Hilar lymphadenopathy	22.70	17.13	11	23142	1848	79719387
Mastitis bacterial	22.69	17.13	5	23148	63	79721172
Implant site infection	22.67	17.13	11	23142	1854	79719381
Jarisch-Herxheimer reaction	22.58	17.13	9	23144	948	79720287
Purpura	22.40	17.13	28	23125	19499	79701736
Atypical mycobacterial lower respiratory tract infection	22.35	17.13	6	23147	179	79721056
Malignant neoplasm progression	22.20	17.13	6	23147	135984	79585251
Contraindicated product administered	22.14	17.13	9	23144	157529	79563706
Bradycardia	22.10	17.13	6	23147	135551	79585684
Testicular mass	22.07	17.13	5	23148	72	79721163
Therapeutic product effect decreased	22.01	17.13	10	23143	163853	79557382
Asthma	21.98	17.13	6	23147	135089	79586146
Clostridium difficile colitis	21.83	17.13	36	23117	32247	79688988
Febrile neutropenia	21.73	17.13	21	23132	230978	79490257
Axonal neuropathy	21.66	17.13	11	23142	2043	79719192
Encephalitis	21.64	17.13	24	23129	14736	79706499
Infection	21.57	17.13	23	23130	241689	79479546
Visual pathway disorder	21.52	17.13	5	23148	81	79721154
Urinary tract infection	21.44	17.13	29	23124	274483	79446752
Stomatitis	21.25	17.13	8	23145	146749	79574486
Depression	21.23	17.13	19	23134	216771	79504464
Hypersensitivity	21.20	17.13	27	23126	262212	79459023
Insomnia	21.14	17.13	24	23129	245146	79476089
Splenomegaly	21.05	17.13	28	23125	20726	79700509
Atrial fibrillation	21.04	17.13	16	23137	197870	79523365
Deafness bilateral	21.02	17.13	11	23142	2174	79719061
Blood bilirubin increased	21.01	17.13	54	23099	66178	79655057
Marrow hyperplasia	20.88	17.13	10	23143	1638	79719597
Hemianopia heteronymous	20.87	17.13	5	23148	93	79721142
Hyperaldosteronism	20.85	17.13	7	23146	453	79720782
Phalangeal hypoplasia	20.80	17.13	4	23149	24	79721211
Intentional overdose	20.80	17.13	3	23150	105957	79615278
Conductive deafness	20.68	17.13	6	23147	239	79720996
Influenza	20.64	17.13	6	23147	129600	79591635
Splenic infarction	20.61	17.13	13	23140	3651	79717584
COVID-19	20.59	17.13	10	23143	157664	79563571
Intracranial pressure increased	20.57	17.13	18	23135	8304	79712931
Iridocyclitis	20.48	17.13	13	23140	3691	79717544
Autoimmune haemolytic anaemia	20.46	17.13	18	23135	8362	79712873
Systemic lupus erythematosus	20.44	17.13	5	23148	121144	79600091
Corneal deposits	20.30	17.13	7	23146	491	79720744
Cerebrovascular accident	20.05	17.13	10	23143	155282	79565953
Cell death	19.97	17.13	14	23139	4685	79716550
Renal atrophy	19.91	17.13	10	23143	1815	79719420
Congenital foot malformation	19.69	17.13	4	23149	33	79721202
Normochromic normocytic anaemia	19.68	17.13	17	23136	7710	79713525
Granulomatous lymphadenitis	19.62	17.13	6	23147	287	79720948
Brain oedema	19.60	17.13	30	23123	25233	79696002
Immune thrombocytopenia	19.58	17.13	25	23128	17780	79703455
Oropharyngeal pain	19.48	17.13	4	23149	109349	79611886
Choroiditis	19.40	17.13	9	23144	1372	79719863
Lichenoid keratosis	19.40	17.13	13	23140	4044	79717191
Optic atrophy	19.37	17.13	10	23143	1923	79719312
Stevens-Johnson syndrome	19.23	17.13	38	23115	39128	79682107
Splenic abscess	19.08	17.13	7	23146	589	79720646
Haemolysis	19.07	17.13	21	23132	12791	79708444
Psoas abscess	18.69	17.13	8	23145	1009	79720226
Anxiety	18.66	17.13	27	23126	248485	79472750
Papilloedema	18.54	17.13	15	23138	6218	79715017
Pancreatitis acute	18.45	17.13	43	23110	49561	79671674
Pseudomembranous colitis	18.28	17.13	14	23139	5360	79715875
Type III immune complex mediated reaction	18.20	17.13	7	23146	671	79720564
Hypermetabolism	18.12	17.13	6	23147	372	79720863
Haemoptysis	18.12	17.13	46	23107	55953	79665282
Cytomegalovirus chorioretinitis	18.02	17.13	14	23139	5476	79715759
Coma hepatic	18.00	17.13	8	23145	1105	79720130
Gamma-glutamyltransferase increased	17.78	17.13	45	23108	54635	79666600
Hepatitis cholestatic	17.74	17.13	21	23132	13831	79707404
AIDS related complication	17.63	17.13	4	23149	58	79721177
Musculoskeletal stiffness	17.54	17.13	15	23138	174993	79546242
Drug hypersensitivity	17.46	17.13	38	23115	298878	79422357
Chylothorax	17.29	17.13	7	23146	768	79720467
Cardiac failure congestive	17.17	17.13	10	23143	142392	79578843

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J04AK02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Other drugs for treatment of tuberculosis
ATC	J04AM03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM07	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
FDA EPC	N0000175483	Antimycobacterial
CHEBI has role	CHEBI:33231	antitubercular agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000995	Antitubercular Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute tuberculosis	indication	25629007
Pulmonary tuberculosis	indication	154283005	DOID:2957
Tuberculosis of meninges	off-label use	58437007
Atypical mycobacterial infection	off-label use	111812000
Pulmonary Mycobacterium avium complex infection	off-label use	186342000
Diabetic retinopathy	contraindication	4855003	DOID:8947
Optic neuritis	contraindication	66760008	DOID:1210
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Bilateral cataracts	contraindication	95722004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.58	Basic
pKa2	5.58	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		IC50	5.48	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		IC50	5.15	WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		IC50	5.16	WOMBAT-PK
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6.25	WOMBAT-PK
Cytochrome P450 3A5	Enzyme	P20815	CP3A5_HUMAN		IC50	4.72	WOMBAT-PK
Probable arabinosyltransferase A	Enzyme		EMBA_MYCTU	INHIBITOR			CHEMBL	CHEMBL
Probable arabinosyltransferase B	Enzyme		EMBB_MYCTO				WOMBAT-PK
Probable arabinosyltransferase C	Enzyme		EMBC_MYCTU				WOMBAT-PK
Probable arabinosyltransferase A	Enzyme		EMBA_MYCTO				WOMBAT-PK

External reference:

ID	Source
4019747	VUID
N0000147838	NUI
D00878	KEGG_DRUG
1070-11-7	SECONDARY_CAS_RN
4017912	VANDF
4019747	VANDF
C0014964	UMLSCUI
CHEBI:4877	CHEBI
95E	PDB_CHEM_ID
CHEMBL44884	ChEMBL_ID
CHEMBL1788373	ChEMBL_ID
DB00330	DRUGBANK_ID
CHEMBL3140361	ChEMBL_ID
CHEMBL1628240	ChEMBL_ID
D004977	MESH_DESCRIPTOR_UI
14052	PUBCHEM_CID
1074	INN_ID
8G167061QZ	UNII
142435	RXNORM
32076	MMSL
4692	MMSL
d00068	MMSL
002850	NDDF
004868	NDDF
24450004	SNOMEDCT_US
26346008	SNOMEDCT_US
387129004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ETHAMBUTOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-101	TABLET, FILM COATED	100 mg	ORAL	ANDA	17 sections
ETHAMBUTOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-101	TABLET, FILM COATED	100 mg	ORAL	ANDA	17 sections
ETHAMBUTOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-102	TABLET, FILM COATED	400 mg	ORAL	ANDA	17 sections
ETHAMBUTOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-102	TABLET, FILM COATED	400 mg	ORAL	ANDA	17 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2337	TABLET, FILM COATED	100 mg	ORAL	NDA authorized generic	16 sections
Myambutol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2607	TABLET, FILM COATED	400 mg	ORAL	NDA	17 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3948	TABLET, FILM COATED	400 mg	ORAL	ANDA	18 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5140	TABLET	100 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5140	TABLET	100 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5142	TABLET	400 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0977	TABLET	400 mg	ORAL	NDA	10 sections
Myambutol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-2876	TABLET	400 mg	ORAL	NDA	17 sections
Ethambutol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6219	TABLET, FILM COATED	400 mg	ORAL	ANDA	17 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54879-001	TABLET, FILM COATED	100 mg	ORAL	NDA authorized generic	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54879-001	TABLET, FILM COATED	100 mg	ORAL	NDA authorized generic	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54879-002	TABLET, FILM COATED	400 mg	ORAL	NDA authorized generic	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54879-002	TABLET, FILM COATED	400 mg	ORAL	NDA authorized generic	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	55695-023	TABLET, FILM COATED	100 mg	ORAL	NDA authorized generic	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	55695-035	TABLET, FILM COATED	400 mg	ORAL	NDA authorized generic	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	61748-011	TABLET, FILM COATED	100 mg	ORAL	ANDA	17 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	61748-014	TABLET, FILM COATED	400 mg	ORAL	ANDA	17 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68084-280	TABLET	400 mg	ORAL	ANDA	18 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68084-280	TABLET	400 mg	ORAL	ANDA	18 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68151-0149	TABLET	100 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68180-280	TABLET	100 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68180-280	TABLET	100 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68180-281	TABLET	400 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68180-281	TABLET	400 mg	ORAL	ANDA	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68850-004	TABLET, FILM COATED	100 mg	ORAL	NDA authorized generic	16 sections
Ethambutol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68850-005	TABLET, FILM COATED	400 mg	ORAL	NDA authorized generic	16 sections